BASF's Evonik Bid Stalls as Valuation Gap and Union Pushback Cloud Chemicals Merger

BASF's roughly 22.15-euro-per-share Evonik approach was turned down; RAG-Stiftung's 44% stake and union resistance cloud the deal's path.

BASF's ambition to consolidate the German specialty chemicals landscape has run into a double wall: Evonik's rejection of its opening offer and mounting resistance from labor representatives. The Ludwigshafen-based giant confirmed on Friday that it had entered exploratory talks with RAG-Stiftung and Evonik Industries over a potential combination — only to see its first concrete proposal dismissed as too low a day later.

A 22.15-Euro Offer That Failed to Convince

According to media reports, BASF pitched roughly 22.15 euros per Evonik share, valuing the Essen-based group's equity at approximately 10.3 billion euros. While that represented a premium of nearly 29 percent over the stock price before the first speculation surfaced, Evonik's management turned it down outright, saying it offered no sufficient basis for formal negotiations or a due diligence review.

BASF declined to comment on pricing details, stressing instead its disciplined approach and noting that any synergies can only be reliably quantified with Evonik's cooperative involvement. Neither side has indicated whether the exploratory talks will continue, or in what form.

RAG-Stiftung Holds the Keys

The ownership structure of the target remains a decisive hurdle. RAG-Stiftung controls around 44 percent of Evonik's shares, giving it what amounts to a blocking minority. Without the foundation's explicit backing, a voluntary public offer to shareholders stands little chance. Analysts at DZ Bank rate Evonik a buy with a price target of 22 euros, emphasizing that beyond financing structure and additional savings potential, the foundation's stance will ultimately determine the outcome of negotiations.

IGBCE Demands Commitments on Jobs and Sites

Union skepticism added another layer of complication. IGBCE chairman Michael Vassiliadis made clear that greater corporate scale alone secures neither jobs nor production sites, calling on decision-makers to provide binding future prospects and investment commitments for the workforce. Those reservations land on two companies already deep in their own cost-cutting programs. Evonik plans to shed 3,200 positions between 2027 and 2029, while BASF is trimming jobs in Germany and pushing major projects in the Chinese market instead.

The structural backdrop in European chemicals amplifies the stakes. High energy costs, bureaucratic requirements and growing import pressure from Asian producers are weighing on the domestic base chemicals industry. A merger might unlock synergies, but it would not resolve Germany's locational disadvantages on its own.

Deutsche Bank Sizes Up the Financial Stretch

The central question in the coming weeks concerns BASF's financial pain threshold. An acquisition of this magnitude would demand substantial resources. Virginie Boucher-Ferte, an analyst at Deutsche Bank Research, put the dimension in precise terms: a purchase price of 25 euros per Evonik share would equal roughly 35 percent of BASF's current market value. She also stressed that the takeover debate is already "out of the bottle" even without a formal deal. For investors, the issue is whether management is prepared to accept meaningful leverage in exchange for scale advantages, or whether capital discipline takes priority.

Bernstein Keeps Outperform but Flags Complexity

Bernstein Research offered some tailwind for a constructive view. The firm maintained its "Outperform" rating with a price target of 61 euros, trimming the objective modestly from 63 euros previously, while noting that the numbers behind a combination look attractive on paper. At the same time, Bernstein explicitly warned that the investment story becomes significantly more complex because of the deal.

That captures the risk scenario: if BASF's leadership engages in a costly bidding war, high valuation premiums loom. Raising the offer would tie up considerable funds that could otherwise go toward the company's ongoing restructuring. Integration of a large corporation in a still-challenging industry environment carries substantial execution risks. Should synergies fail to materialize or integration costs spiral, BASF faces a market de-rating, with investors fearing that strategic size is being prioritized over financial returns.

Buybacks, India MDI Study and Chart Levels

On the operational front, BASF has levers beyond large-scale M&A. In the growth market of India, the company is advancing a feasibility study for MDI production. Subsidiary BASF India Polyurethanes Private Limited has already secured an industrial plot in Dahej. Add innovations such as new binders with a reduced CO2 footprint, and the group demonstrates it remains capable of acting organically.

Shareholder returns are also in play. Between September 21 and 25, BASF repurchased 838,832 of its own shares. The stock closed yesterday at 50.31 euros, a daily loss of 1.1 percent, though it remains up 13 percent since the start of the year.

Technically, the chart offers initial orientation. As long as the shares trade above the 200-day moving average of 49.57 euros, the broader trend stays intact. A break below that mark would open further downside potential and lend technical support to the bearish case.

October 28 Marks the Next Catalyst

The next major fundamental catalyst is set: on October 28, 2026, BASF will publish its interim report for the third quarter of 2026. Management will have to answer questions at the accompanying investor conference. Until then, the trajectory of talks with Evonik and RAG-Stiftung remains the dominant driver for the stock.